Now Playing
Opinion|Videos|September 16, 2024
Chronic Graft-versus-Host Disease: Understanding the Disease and Its Widespread Symptoms
Panelists discuss how chronic graft-versus-host disease (cGVHD) differs from acute GVHD, its main challenges for patients, and its common symptoms and impact on daily life.
Advertisement
Episodes in this series
- Can you provide some background on cGVHD? How does it differ from acute GVHD, and what are the main challenges it presents for patients?
- From your experience, what are the most common symptoms you see in cGVHD patients, and how do these symptoms impact their daily lives?
Advertisement
Related to this article
In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.
At ASTRO 2026, Suresh Rana details how AI-driven contouring accelerates care timelines, requiring rigorous team monitoring and early nursing input.
At ASTRO 2026, Dr. Erica Braschi Jordan details toxicity tracking, physical therapy referral, and quality of life in proton regional nodal irradiation.
At ASTRO 2026, Dr. Mishaal Munir details how nurse-led triage workflows and prompt symptom escalations improve care for breast cancer brain metastases.
ASTRO 2026 presenter Kayla Kafka-Peterson details an Adapt-Adopt-Build model to bridge global brachytherapy nursing gaps and standardize perioperative care.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Anktiva Plus BCG: Telling Expected Immune Effects From Red Flags
2
Automated Breast Ultrasound Tied to Fewer False-Positives in Dense Breasts
3
Future Directions in Metastatic Triple-Negative Breast Cancer Care
4
Delaying BSO to Age 50 Leaves BRCA1 Carriers With 24% Ovarian Cancer Risk
5